BIBLIOGRAFÍA

SECCIÓN F.
Agentes terapéuticos

CAPÍTULO 93.
Antibacterianos, antivirales y antimicoticos de uso común

1. Bliziotis, I.A., Samonis, G., Vardakas, K.,Z., Chrysanthopoulou, S., Falagas, M.E. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. *Clin. Infect. Dis* 2005;41:149
2. Bradley, J.S., Jackson, M.A., and The Committee On Infectious Diseases. The use of systemic and topical fluoroquinoles. www.pediatrics.org/cgi/doi/10.1542/peds.2011-1496 doi:10.1542/peds.2011-1496
3. CDC https://www.cdc.gov/antibiotic-use/index.html
4. CDC. Influenza Antiviral Medications: Summary for Clinicians https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm
5. *Cuadro Básico de Medicamentos del Sector Salud*. México. http://www.imss.gob.mx/profesionales-salud/cuadros-basicos
6. Durand GA, Raoult D, Dubourg G. Antibiotic discovery: History, methods and perspectives, Intern J Antimicrob Agents (2018), doi: https://doi.org/10.1016/j.ijantimicag.2018.11.010
7. Gilbert DN, Chambers HF. Eliopoulos GM, Saag MS, Pavia AT. The Sanford Guide to Antimicrobial Therapy 2018. 48th ed. Antimicrobial Therapy Inc., 2018, Sperryville, VA, USA.
8. HSE Clinical Programme in Obstetrics and Gynaecology-Medication Guidelines For Obstetrics and Gynaecology. First Edition. Volume 2. Antimicrobial safety In Pregnancy and Lactation. 2017 https://www.hse.ie/eng/services/publications/clinical-strategy-and-programmes/antimicrobial-safety-in-pregnancy-and-lactation.pdf
9. IDSA, Antimicrobial agent use. http://www.idsociety.org/Antimicrobial_Agents/
10. Leekha, S., Terrell, C.L., Edson, R.S. General Principles of Antimicrobial Therapy. *Mayo. Clin. Proc.*, 2011;86:156
11. Liu, C., Bayer, A., Cosgrove, S.E., et al: Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin. Infect. Dis.*, 2011;52: e18
12. Miranda, N.M.G., Leaños, M.B., Vilchis, P.M., Solórzano, S.F.: In vitro activity effects of combinations of cephalotin, dicloxacillin, imipenem, vancomycin and amikacin against meticillin-resistant *Staphylococcus* spp. strains. *Ann. Clin. Microbiol. Antimicrob.*, 2006; 5:25.
13. Rivas G, Cardona-Castro N. Antimicóticos de uso sistémico: ¿Con que opciones terapéuticas contamos?. *CES Medicina* 2009;23:61-76
14. Shallcross, L.J., Davies, S.C., The World Health Assembly resolution on antimicrobial resistance. J Antimicrob Chemother. 2014 ;69:2883.
15. Sharland, M: SACAR Paediatric Subgroup. The use of antibacterials in children: a report of the Specialist Advisory Committee on Antimicrobial Resistance (SACAR) Paediatric Subgroup. *J. Antimicrob. Chemother.*, 2007;60 (Suppl 1): i15-26.
16. Wunderink, R., Waterer, G.W. Community-Acquired Pneumonia. *N Engl J Med* , 2014;370:543

CAPÍTULO 94.
Nuevos antimicrobianos

1. Alexander E, Goldberg L, Das AF, Moran GJ, Sandrock C, Gasink LB, Spera P, Sweeney C, Paukner S, Wicha WW, Gelone SP, Schranz J: Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial. JAMA 2019, 322(17):1661-1671.
2. Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, Srinivasan A, Dellit TH, Falck-Ytter YT, Fishman NO, Hamilton CW, Jenkins TC, Lipsett PA, Malani PN, May LS, Moran GJ, Neuhauser MM, Newland JG, Ohl CA, Samore MH, Seo SK, Trivedi KK: Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016, 62(10):e51-77.
3. Barnes MD, Taracila MA, Good CE, Bajaksouzian S, Rojas LJ, van Duin D, Kreiswirth BN, Jacobs MR, Haldimann A, Papp-Wallace KM, Bonomo RA: Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC. Antimicrob Agents Chemother 2019, 63(8).
4. Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD: Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 2021, 21(2):226-240.
5. Bianchini ML, Jeffres MN, Campbell JD: Cost-Effectiveness Analysis of New Beta-Lactam Beta-Lactamase Inhibitor Antibiotics Versus Colistin for the Treatment of Carbapenem-Resistant Infections. Hosp Pharm 2022, 57(1):93-100.
6. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J: Bad bugs, no

drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48(1):1-12.
7. Bradford PA, Miller AA, O'Donnell J, Mueller JP: Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrheae, Including Multi-Drug-Resistant Isolates. ACS Infect Dis 2020, 6(6):1332-1345.
8. Bush K, Bradford PA: Epidemiology of beta-Lactamase-Producing Pathogens. Clin Microbiol Rev 2020, 33(2).
9. Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, Gasink LB: Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 2016, 16(6):661-673.
10. Cassini A, Hogberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, Colomb-Cotinat M, Kretzschmar ME, Devleesschauwer B, Cecchini M, Ouakrim DA, Oliveira TC, Struelens MJ, Suetens C, Monnet DL, Burden of AMRCG: Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis 2019, 19(1):56-66.
11. Cho JC, Crotty MP, Pardo J: Ridinilazole: a novel antimicrobial for Clostridium difficile infection. Ann Gastroenterol 2019, 32(2):134-140.
12. De Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA, Paterson DL, Walker MJ: Antimicrobial Resistance in ESKAPE Pathogens. Clin Microbiol Rev 2020, 33(3).
13. Dellit TH, Owens RC, McGowan JE, Jr., Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM, Infectious Diseases Society of A, Society for Healthcare Epidemiology of A: Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44(2):159-177.
14. Durand-Reville TF, Guler S, Comita-Prevoir J, Chen B, Bifulco N, Huynh H, Lahiri S, Shapiro AB, McLeod SM, Carter NM, Moussa SH, Velez-Vega C, Olivier NB, McLaughlin R, Gao N, Thresher J, Palmer T, Andrews B, Giacobbe RA, Newman JV, Ehmann DE, de Jonge B, O'Donnell J, Mueller JP, Tommasi RA, Miller AA: ETX2514 is a broad-spectrum beta-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol 2017, 2:17104.
15. Emeraud C, Escaut L, Boucly A, Fortineau N, Bonnin RA, Naas T, Dortet L: Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-beta-Lactamase-Producing Gram-Negative Bacteria. Antimicrob Agents Chemother 2019, 63(5).
16. Falcone M, Tiseo G, Leonildi A, Della Sala L, Vecchione A, Barnini S, Farcomeni A, Menichetti F: Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2022, 66(5):e0214221.
17. Falcone M, Tiseo G, Nicastro M, Leonildi A, Vecchione A, Casella C, Forfori F, Malacarne P, Guarracino F, Barnini S, Menichetti F: Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients. Clin Infect Dis 2021, 72(11):2021-2024.
18. File TM, Goldberg L, Das A, Sweeney C, Saviski J, Gelone SP, Seltzer E, Paukner S, Wicha WW, Talbot GH, Gasink LB: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial. Clin Infect Dis 2019, 69(11):1856-1867.
19. Foti C, Piperno A, Scala A, Giuffre O: Oxazolidinone Antibiotics: Chemical, Biological and Analytical Aspects. Molecules 2021, 26(14).
20. Garner MJ, Carson C, Lingohr EJ, Fazil A, Edge VL, Trumble Waddell J: An assessment of antimicrobial resistant disease threats in Canada. PLoS One 2015, 10(4):e0125155.
21. Garza-Gonzalez E, Bocanegra-Ibarias P, Bobadilla-Del-Valle M, Ponce-de-Leon-Garduno LA, Esteban-Kenel V, Silva-Sanchez J, Garza-Ramos U, Barrios-Camacho H, Lopez-Jacome LE, Colin-Castro CA, Franco-Cendejas R, Flores-Trevino S, Morfin-Otero R, Rojas-Larios F, Mena-Ramirez JP, Fong-Camargo MG, Morales-De-la-Pena CT, Garcia-Mendoza L, Choy-Chang EV, Aviles-Benitez LK, Feliciano-Guzman JM, Lopez-Gutierrez E, Gil-Veloz M, Barajas-Magallon JM, Aguirre-Burciaga E, Lopez-Moreno LI, Martinez-Villarreal RT, Canizales-Oviedo JL, Cetina-Umana CM, Romero-Romero D, Bello-Pazos FD, Barlandas-Rendon NRE, Maldonado-Anicacio JY, Bolado-Martinez E, Galindo-Mendez M, Perez-Vicelis T, Alavez-Ramirez N, Mendez-Sotelo BJ, Cabriales-Zavala JF, Nava-Pacheco YC, Moreno-Mendez MI, Garcia-Romo R, Silva-Gamino AR, Avalos-Aguilera AM, Santiago-Calderon MA, Lopez-Garcia M, Velazquez-Acosta MDC, Cobos-Canul DI, Vazquez-Larios MDR, Ortiz-Porcayo AE, Guerrero-Nunez AE, Valero-Guzman J, Rosales-Garcia AA, Ostos-Cantu HL, Camacho-Ortiz A: Drug resistance phenotypes and genotypes in Mexico in representative gram-negative species: Results from the infivar network. PLoS One 2021, 16(3):e0248614.
22. Garza-Gonzalez E, Franco-Cendejas R, Morfin-Otero R, Echaniz-Aviles G, Rojas-Larios F, Bocanegra-Ibarias P, Flores-Trevino S, Ponce-de-Leon A, Rodriguez-Noriega E, Alavez-Ramirez N, Mena-Ramirez JP, Rincon-Zuno J, Fong-Camargo MG, Morales-De-la-Pena CT, Huerta-Baltazar CR, Lopez-Jacome LE, Carnalla-Barajas MN, Soto-Nogueron A, Sanchez-Francia D, Moncada-Barron D, Ortiz-Brizuela E, Garcia-Mendoza L, Newton-Sanchez OA, Choy-Chang EV, Aviles-Benitez LK, Martinez-Miranda R, Feliciano-Guzman JM, Pena-Lopez CD, Couoh-May CA, Lopez-Gutierrez E, Gil-Veloz M, Armenta-Rodriguez LC, Manriquez-Reyes M, Gutierrez-Brito M, Lopez-Ovilla I, Adame-Alvarez C, Barajas-Magallon JM, Aguirre-Burciaga E, Coronado-Ramirez AM, Rosales-Garcia AA, Sida-Rodriguez S, Urbina-Rodriguez RE, Lopez-Moreno LI, Juarez-Velazquez GE, Martinez-Villarreal RT, Canizales-Oviedo JL, Cetina-Umana CM, Perez-Juarez MM, Gonzalez-Moreno A, Romero-Romero D, Bello-Pazos FD, Aguilar-Orozco G, Barlandas-Rendon NRE, Maldonado-Anicacio JY, Valadez-Quiroz A, Camacho-Ortiz A: The Evolution of Antimicrobial Resistance in Mexico During the Last Decade: Results from the INVIFAR Group. Microb Drug Resist 2020, 26(11):1372-1382.
23. Garza-Gonzalez E, Morfin-Otero R, Mendoza-Olazaran S, Bocanegra-Ibarias P, Flores-Trevino S, Rodriguez-Noriega

E, Ponce-de-Leon A, Sanchez-Francia D, Franco-Cendejas R, Arroyo-Escalante S, Velazquez-Acosta C, Rojas-Larios F, Quintanilla LJ, Maldonado-Anicacio JY, Martinez-Miranda R, Ostos-Cantu HL, Gomez-Choel A, Jaime-Sanchez JL, Aviles-Benitez LK, Feliciano-Guzman JM, Pena-Lopez CD, Couoh-May CA, Molina-Jaimes A, Vazquez-Narvaez EG, Rincon-Zuno J, Rivera-Garay R, Galindo-Espinoza A, Martinez-Ramirez A, Mora JP, Corte-Rojas RE, Lopez-Ovilla I, Monroy-Colin VA, Barajas-Magallon JM, Morales-De-la-Pena CT, Aguirre-Burciaga E, Coronado-Ramirez M, Rosales-Garcia AA, Ayala-Tarin MD, Sida-Rodriguez S, Perez-Vega BA, Navarro-Rodriguez A, Juarez-Velazquez GE, Cetina-Umana CM, Mena-Ramirez JP, Canizales-Oviedo J, Moreno-Mendez MI, Romero-Romero D, Arevalo-Mejia A, Cobos-Canul DI, Aguilar-Orozco G, Silva-Sanchez J, Camacho-Ortiz A: A snapshot of antimicrobial resistance in Mexico. Results from 47 centers from 20 states during a six-month period. PLoS One 2019, 14(3):e0209865.

24. Hamrick JC, Docquier JD, Uehara T, Myers CL, Six DA, Chatwin CL, John KJ, Vernacchio SF, Cusick SM, Trout REL, Pozzi C, De Luca F, Benvenuti M, Mangani S, Liu B, Jackson RW, Moeck G, Xerri L, Burns CJ, Pevear DC, Daigle DM: VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-beta-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2020, 64(3).
25. 25. Hernandez-Garcia M, Castillo-Polo JA, Cordero DG, Perez-Viso B, Garcia-Castillo M, Saez de la Fuente J, Morosini MI, Canton R, Ruiz-Garbajosa P: Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection. J Clin Microbiol 2022, 60(3):e0224521.
26. Hernandez-Garcia M, Garcia-Castillo M, Ruiz-Garbajosa P, Bou G, Siller-Ruiz M, Pitart C, Gracia-Ahufinger I, Mulet X, Pascual A, Tormo N, Canton R: In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain. Antimicrob Agents Chemother 2022, 66(3):e0216121.
27. Huang DB, Strader CD, MacDonald JS, VanArendonk M, Peck R, Holland T: An Updated Review of Iclaprim: A Potent and Rapidly Bactericidal Antibiotic for the Treatment of Skin and Skin Structure Infections and Nosocomial Pneumonia Caused by Gram-Positive Including Multidrug-Resistant Bacteria. Open Forum Infect Dis 2018, 5(2):ofy003.
28. Ito A, Sato T, Ota M, Takemura M, Nishikawa T, Toba S, Kohira N, Miyagawa S, Ishibashi N, Matsumoto S, Nakamura R, Tsuji M, Yamano Y: In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria. Antimicrob Agents Chemother 2018, 62(1).
29. Jorgensen SCJ, Trinh TD, Zasowski EJ, Lagnf AM, Bhatia S, Melvin SM, Steed ME, Simon SP, Estrada SJ, Morrisette T, Claeys KC, Rosenberg JR, Davis SL, Rybak MJ: Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections. Open Forum Infect Dis 2019, 6(12):ofz522.
30. Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, Palmore TN, Rhee C, Klompas M, Dekker JP, Powers JH, 3rd, Suffredini AF, Hooper DC, Fridkin S, Danner RL, National Institutes of Health Antimicrobial Resistance Outcomes Research I: Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clin Infect Dis 2018, 67(12):1803-1814.
31. Kadri SS, Lai YL, Warner S, Strich JR, Babiker A, Ricotta EE, Demirkale CY, Dekker JP, Palmore TN, Rhee C, Klompas M, Hooper DC, Powers JH, 3rd, Srinivasan A, Danner RL, Adjemian J, forming the National Insititutes of Health Antimicrobial Resistance Outcomes Research I: Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals. Lancet Infect Dis 2021, 21(2):241-251.
32. Karlowsky JA, Biedenbach DJ, Kazmierczak KM, Stone GG, Sahm DF: Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC beta-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014. Antimicrob Agents Chemother 2016, 60(5):2849-2857.
33. Lakhundi S, Zhang K: Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology. Clin Microbiol Rev 2018, 31(4).
34. Livermore DM, Mushtaq S, Warner M, Turner SJ, Woodford N: Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens. J Antimicrob Chemother 2018, 73(1):126-133.
35. Lomovskaya O, Rubio-Aparicio D, Nelson K, Sun D, Tsivkovski R, Castanheira M, Lindley J, Loutit J, Dudley M: In Vitro Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2021, 65(6).
36. Lomovskaya O, Rubio-Aparicio D, Tsivkovski R, Loutit J, Dudley M: The Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 Restores the Potency of Multiple Oral Beta-Lactam Antibiotics against Beta-Lactamase-Producing Strains of Resistant Enterobacterales. Antimicrob Agents Chemother 2022, 66(2):e0216821.
37. Lomovskaya O, Tsivkovski R, Sun D, Reddy R, Totrov M, Hecker S, Griffith D, Loutit J, Dudley M: QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics. Front Microbiol 2021, 12:697180.
38. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18(3):268-281.
39. Martin-Loeches I, Timsit JF, Kollef MH, Wunderink RG, Shime N, Novacek M, Kivistik U, Rea-Neto A, Bruno CJ, Huntington JA, Lin G, Jensen EH, Motyl M, Yu B, Gates D, Butterton JR, Rhee EG: Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia. J Antimicrob Chemother 2022, 77(4):1166-1177.

40. Mauri C, Maraolo AE, Di Bella S, Luzzaro F, Principe L: The Revival of Aztreonam in Combination with Avibactam against Metallo-beta-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases. Antibiotics (Basel) 2021, 10(8).
41. Morfin-Otero R, Tinoco-Favila JC, Sader HS, Salcido-Gutierrez L, Perez-Gomez HR, Gonzalez-Diaz E, Petersen L, Rodriguez-Noriega E: Resistance trends in gram-negative bacteria: surveillance results from two Mexican hospitals, 2005-2010. BMC Res Notes 2012, 5:277.
42. Morrissey I, Magnet S, Hawser S, Shapiro S, Knechtle P: In Vitro Activity of Cefepime-Enmetazobactam against Gram-Negative Isolates Collected from U.S. and European Hospitals during 2014-2015. Antimicrob Agents Chemother 2019, 63(7).
43. Motsch J, Murta de Oliveira C, Stus V, Koksal I, Lyulko O, Boucher HW, Kaye KS, File TM, Brown ML, Khan I, Du J, Joeng HK, Tipping RW, Aggrey A, Young K, Kartsonis NA, Butterton JR, Paschke A: RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Clin Infect Dis 2020, 70(9):1799-1808.
44. Mushtaq S, Garello P, Vickers A, Woodford N, Livermore DM: Activity of cefepime/zidebactam (WCK 5222) against 'problem' antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory. J Antimicrob Chemother 2021, 76(6):1511-1522.
45. Mushtaq S, Meunier D, Vickers A, Woodford N, Livermore DM: Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases. J Antimicrob Chemother 2021, 76(2):434-442.
46. Mushtaq S, Vickers A, Doumith M, Ellington MJ, Woodford N, Livermore DM: Activity of beta-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 2021, 76(1):160-170.
47. McKinnell JA, Dwyer JP, Talbot GH, Connolly LE, Friedland I, Smith A, Jubb AM, Serio AW, Krause KM, Daikos GL, Group CS: Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae. N Engl J Med 2019, 380(8):791-793.
48. Miller AA, Shapiro AB, McLeod SM, Carter NM, Moussa SH, Tommasi R, Mueller JP: In Vitro Characterization of ETX1317, a Broad-Spectrum beta-Lactamase Inhibitor That Restores and Enhances beta-Lactam Activity against Multi-Drug-Resistant Enterobacteriales, Including Carbapenem-Resistant Strains. ACS Infect Dis 2020, 6(6):1389-1397.
49. Nieuwlaat R, Mbuagbaw L, Mertz D, Burrows LL, Bowdish DME, Moja L, Wright GD, Schunemann HJ: Coronavirus Disease 2019 and Antimicrobial Resistance: Parallel and Interacting Health Emergencies. Clin Infect Dis 2021, 72(9):1657-1659.
50. O'Donnell J, Tanudra A, Chen A, Hines D, Tommasi R, Mueller J: Pharmacokinetic/Pharmacodynamic Determination and Preclinical Pharmacokinetics of the beta-Lactamase Inhibitor ETX1317 and Its Orally Available Prodrug ETX0282. ACS Infect Dis 2020, 6(6):1378-1388.
51. Partridge SR, Kwong SM, Firth N, Jensen SO: Mobile Genetic Elements Associated with Antimicrobial Resistance. Clin Microbiol Rev 2018, 31(4).
52. Paterson DL: "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004, 38 Suppl 4:S341-345.
53. Pogue JM, Kaye KS, Veve MP, Patel TS, Gerlach AT, Davis SL, Puzniak LA, File TM, Olson S, Dhar S, Bonomo RA, Perez F: Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa. Clin Infect Dis 2020, 71(2):304-310.
54. Pullman J, Gardovskis J, Farley B, Sun E, Quintas M, Lawrence L, Ling R, Cammarata S, Group PS: Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study. J Antimicrob Chemother 2017, 72(12):3471-3480.
55. Rice LB: Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008, 197(8):1079-1081.
56. Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, Pascual A: Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. Clin Microbiol Rev 2018, 31(2).
57. Sabet M, Tarazi Z, Griffith DC: In Vivo Activity of QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor, in Combination with Beta-Lactams against Carbapenem-Resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2020, 64(11).
58. Sader HS, Castanheira M, Duncan LR, Flamm RK: Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015-2016. Diagn Microbiol Infect Dis 2018, 92(1):69-74.
59. Sader HS, Castanheira M, Mendes RE, Flamm RK, Jones RN: Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014. Antimicrob Agents Chemother 2017, 61(4).
60. Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK, Castanheira M: Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates. Antimicrob Agents Chemother 2018, 62(1).
61. Sader HS, Rhomberg PR, Flamm RK, Jones RN, Castanheira M: WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant beta-lactamases. J Antimicrob Chemother 2017, 72(6):1696-1703.
62. Seifert H, Stefanik D, Sutcliffe JA, Higgins PG: In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents 2018, 51(1):62-64.
63. Shapiro AB, Moussa SH, McLeod SM, Durand-Reville T, Miller AA: Durlobactam, a New Diazabicyclooctane beta-Lactamase Inhibitor for the Treatment of Acinetobacter Infections in Combination With Sulbactam. Front Microbiol 2021, 12:709974.
64. Soriano A, Carmeli Y, Omrani AS, Moore LSP, Tawadrous M, Irani P: Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Op-

tions: A Systematic Literature Review. Infect Dis Ther 2021, 10(4):1989-2034.
65. Talbot GH, Jezek A, Murray BE, Jones RN, Ebright RH, Nau GJ, Rodvold KA, Newland JG, Boucher HW, Infectious Diseases Society of A: The Infectious Diseases Society of America's 10 x '20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 x '20 a Possibility? Clin Infect Dis 2019, 69(1):1-11.
66. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ: Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum beta-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis 2021, 72(7):1109-1116.
67. Titov I, Wunderink RG, Roquilly A, Rodriguez Gonzalez D, David-Wang A, Boucher HW, Kaye KS, Losada MC, Du J, Tipping R, Rizk ML, Patel M, Brown ML, Young K, Kartsonis NA, Butterton JR, Paschke A, Chen LF: A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). Clin Infect Dis 2021, 73(11):e4539-e4548.
68. Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M, De Rosa FG, Sarmati L, Bassetti M, Brindicci G, Rossi M, Luzzati R, Grossi PA, Corona A, Capone A, Falcone M, Mussini C, Trecarichi EM, Cascio A, Guffanti E, Russo A, De Pascale G, Tascini C, Gentile I, Losito AR, Bussini L, Corti G, Ceccarelli G, Corcione S, Compagno M, Giacobbe DR, Saracino A, Fantoni M, Antinori S, Peghin M, Bonfanti P, Oliva A, De Gasperi A, Tiseo G, Rovelli C, Meschiari M, Shbaklo N, Spanu T, Cauda R, Viale P: Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study. Clin Infect Dis 2021, 73(9):1664-1676.
69. Versporten A, Zarb P, Caniaux I, Gros MF, Drapier N, Miller M, Jarlier V, Nathwani D, Goossens H, Global PPSn: Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. Lancet Glob Health 2018, 6(6):e619-e629.
70. Wu J, Cao G, Wu H, Chen Y, Guo B, Wu X, Yu J, Ni K, Qian J, Wang L, Wu J, Wang Y, Yuan H, Zhang J, Xi Y: Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers. Antimicrob Agents Chemother 2020, 64(6).
71. Wu W, Feng Y, Tang G, Qiao F, McNally A, Zong Z: NDM Metallo-beta-Lactamases and Their Bacterial Producers in Health Care Settings. Clin Microbiol Rev 2019, 32(2).
72. Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, Cornely OA, Solomkin J, Bhowmick T, Bishara J, Daikos GL, Felton T, Furst MJL, Kwak EJ, Menichetti F, Oren I, Alexander EL, Griffith D, Lomovskaya O, Loutit J, Zhang S, Dudley MN, Kaye KS: Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infect Dis Ther 2018, 7(4):439-455.
73. Wunderink RG, Matsunaga Y, Ariyasu M, Clevenbergh P, Echols R, Kaye KS, Kollef M, Menon A, Pogue JM, Shorr AF, Timsit JF, Zeitlinger M, Nagata TD: Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2021, 21(2):213-225.
74. Wagenlehner FME, Cloutier DJ, Komirenko AS, Cebrik DS, Krause KM, Keepers TR, Connolly LE, Miller LG, Friedland I, Dwyer JP, Group ES: Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med 2019, 380(8):729-740.
75. Yahara K, Ma KC, Mortimer TD, Shimuta K, Nakayama SI, Hirabayashi A, Suzuki M, Jinnai M, Ohya H, Kuroki T, Watanabe Y, Yasuda M, Deguchi T, Eldholm V, Harrison OB, Maiden MCJ, Grad YH, Ohnishi M: Emergence and evolution of antimicrobial resistance genes and mutations in Neisseria gonorrhoeae. Genome Med 2021, 13(1):51.
76. Yahav D, Giske CG, Gramatniece A, Abodakpi H, Tam VH, Leibovici L: New beta-Lactam-beta-Lactamase Inhibitor Combinations. Clin Microbiol Rev 2020, 34(1).
77. Zhang Y, Zhao C, Wang Q, Wang X, Chen H, Li H, Zhang F, Wang H: Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli. J Antimicrob Chemother 2020, 75(9):2609-2615.

CAPÍTULO 95.
Resistencia antimicrobiana.
Un reto

1. Abat C, Rolain J-M, Dubourg G, Fournier P-E, Chaudet H, Raoult D. Evaluating the Clinical Burden and Mortality Attributable to Antibiotic Resistance: The Disparity of Empirical Data and Simple Model Estimations. Clin Infect Dis 2017;65:S58–63.
2. Aminov R. History of antimicrobial drug Discovery: major classes and health impact. Biochem Pharmacol 2017;133(1):4.19.
3. Barlow M, Hall BG. Phylogenetic analysis shows that the OXA beta-lactamase genes have been on plasmids for millions of years. J Mol Evol 2002;55:314–21.
4. Beceiro A, Tomás M, Bou G. Resistencia a los antimicrobianos y virulencia, ¿una asociación beneficiosa para el mundo microbiano? Enferm Infecc Microbiol Clin 2012; 30(8):492-499.
5. Barrios H, Garza U, Reyna F, et al. Isolation of carbapenem-resistant NDM-1-positive Providencia rettgeri in Mexico. J Antimicrob Chemother 2013; 68(8):1934-1936.
6. Bocanegra P, Peña C, Camacho A, et al. Genetic characterization of drug resistance and clonal dynamics of Acinetobacter baumannii in a hospital setting in Mexico. Int J Antimicrob Agent 2015; 45(3):309-313.
7. Bush K, Jacoby GA. Updated Functional Classification of β-Lactamases. Antimicrob Agent Chemother 2010;54(3):969-976.
8. Centers for Disease Control and Prevention. Antibiotic / Antimicrobial Resistance. Biggest Threats.https://www.cdc.gov/drugresistance/biggest_threats.html (fecha de acceso abril 30, 2019).
9. Centers for Disease Control and Prevention. About antimi-

crobial resistance 2018. https://www.cdc.gov/drugresistance/about.html (fecha de acceso abril 30, 2019).
10. Cuéllar JM, Ponce de León A, Quiroz R, et al. Rapid detection of ESBL-producing gram-negative bacteria isolated from blood: a reasonable and reliable tool for middle and low resource countries. Rev Invest Clin 2009; 61(4): 306-312.
11. Charlop-Powers Z, Milshteyn A, Brady SF. Metagenomic small molecule discovery methods. Curr Opin Microbiol 2014;19:70–5.
12. D'Costa VM, McGrann KM, Hughes DW, Wright GD. Sampling the antibiotic resistome. Science 2006;311:374–7.
13. Estrategia Nacional de Acción contra la Resistencia a los Antimicrobianos en México. https://www.gob.mx/cofepris/acciones-y-programas/estrategia-nacional-de-accion-contra-la-resistencia-a-los-antimicrobianos-en-mexico Fleming A. Penicillin. Nobel Lecture. 1945.
14. Galarde-López M, Velazquez-Meza ME, Bobadilla-Del-Valle M, Cornejo-Juárez P, Carrillo-Quiroz BA, Ponce-de-León A, Sassoé-González A, Saturno-Hernández P, Alpuche-Aranda CM. Antimicrobial Resistance Patterns and Clonal Distribution of E. coli, Enterobacter spp. and Acinetobacter spp. Strains Isolated from Two Hospital Wastewater Plants. Antibiotics (Basel). 2022; 11(5): 601.
15. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Lond Engl 2016; 388: 1459–544.
16. Jiang X, Ellabaan MMH, Charusanti P, Munck C, Blin K, Tong Y, et al. Dissemination of antibiotic resistance genes from antibiotic producers to pathogens. Nat Commun 2017; 8: 15784.
17. Kadri S, Adjemian J Lai YL, Spaulding AB, Ricotta E, Prevots DR et al. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clin Infect Dis. 2018 Nov 28; 67(12): 1803-1814.
18. Kaye KS, Gales AC, Dubourg G. Old antibiotics for multidrug-resistant pathogens: from in vitro activity to clinical outcomes. Int J Antimicrob Agents 2017; 49:542–8.
19. Miranda-Novales MG, Flores-Moreno K, López-Vidal Y, Rodríguez-Álvarez M, Solórzano-Santos F, Soto-Hernández JL, Ponce de León-Rosales S; UNCAR Network*. Antimicrobial resistance and antibiotic consumption in Mexican hospitals. Salud Publica Mex. 2020; 62(1):42-49.
20. Mosqueda J, Montaño A, Rolón A, et al. Molecular epidemiology and risk factors of blood stream infections caused by extended spectrum β-lactamase-producing Klebsiella pneumoniae. A case-control study. Int J Infect Dis 2008; 12(6): 653-659.
21. Munita JM, Arias C. Mechanism of Antibiotic resistance. Microbiol Spectr. 2016 April; 4(2): doi:10.1128/microbiolspec.VMBF-0016-2015.
22. OMS. Plan de acción mundial sobre la resistencia a antimicrobianos. 2016 https://www.who.int/antimicrobial-resistance/publications/global-action-plan/es/ (fecha de acceso abril 2019).
23. Pérez H, Robles A. Aspectos básicos de los mecanismos de resistencia bacteriana. Rev Med 2013; 4(3): 187-191.
24. Picozzi SC, Casellato S, Rossini M, et al. Extended-spectrum beta-lactamase-positive Escherichia coli causing complicated upper urinary tract infection: Urologist should act in time. 2014; 6(2): 107-12.
25. Tacconelli E, Sifakis F, Harbarth S, Schrijver R, van Mourik M, Voss A, et al. Surveillance for control of antimicrobial resistance. Lancet Infect Dis 2018;18(3), e99–e106.
26. Torres-González P, Bobadilla-Del Valle M, Tovar-Calderón E, Leal-Vega F, Hernández-Cruz A, Martínez-Gamboa A, et al. Outbreak caused by Enterobacteriaceae harboring NDM-1 metallo-β-lactamase carried in an IncFII plasmid in a tertiary care hospital in Mexico City. Antimicrob Agents Chemother. 2015; 59(11): 7080-3.
27. Waglechner N, Wright GD. Antibiotic resistance: it's bad, but why isn't it worse? BMC Biol 2017;15:84.
28. Wright GD. The antibiotic resistome: the nexus of chemical and genetic diversity. Nat Rev Microbiol 2007;5:175–86.
29. World Health Organization. Antimicrobial resistance, Factsheet 194 2016. http://www.who.int/mediacentre/factsheets/fs194/en/ (fecha de acceso abril 30, 2019).
30. Zumaya-Estrada FA, Ponce-de-León-Garduño A, Ortiz-Brizuela E, Tinoco-Favila JC, Cornejo-Juárez P, Vilar-Compte D, Sassoé-González A, Saturno-Hernandez PJ, Alpuche-Aranda CM. Point Prevalence Survey of Antimicrobial Use in Four Tertiary Care Hospitals in Mexico. Infect Drug Resist. 2021 Nov 2; 14:4553-4566.